BIO-TECHNE Corp Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31)
BIO-TECHNE Corp (TECH) reported Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) of $23.89 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecrease · last filed 2012-05-10
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $23.89M.
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $21.00K.
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2011-09-30 was -$28.00K, a 163.64% decline year-over-year.
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $316.00K.
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for fiscal 2011 was -$85.00K, a 148.57% decline from fiscal 2010.
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for fiscal 2010 was $175.00K, a 91.91% decline from fiscal 2009.
- BIO-TECHNE Corp other comprehensive income (loss), available-for-sale securities adjustment, net of tax (deprecated 2012-01-31) for fiscal 2009 was $2.16M.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $23.89M 10-Q · filed 2012-05-10 | $23.91M derived: sum of 2 quarters · filed 2012-05-10 | $23.88M 10-Q · filed 2012-05-10 | $24.20M derived: sum of 4 quarters · filed 2012-05-10 |
| 2011-12-31 | $21.00K 10-Q · filed 2012-02-07 | -$7.00K 10-Q · filed 2012-02-07 | $309.00K derived: sum of 3 quarters · filed 2012-02-07 | $245.00K derived: sum of 4 quarters · filed 2012-05-10 |
| 2011-09-30 | -$28.00K 10-Q · filed 2011-11-09 | $288.00K derived: sum of 2 quarters · filed 2011-11-09 | $224.00K derived: sum of 3 quarters · filed 2012-05-10 | -$157.00K derived: sum of 4 quarters · filed 2012-05-10 |
| 2011-06-30 | $316.00K derived: 10-K 12 month − 10-Q 9 month · filed 2011-08-29 | $252.00K derived: sum of 2 quarters · filed 2012-05-10 | -$129.00K derived: sum of 3 quarters · filed 2012-05-10 | -$85.00K 10-K · filed 2011-08-29 |
| 2011-03-31 | -$64.00K 10-Q · filed 2012-05-10 | -$445.00K derived: sum of 2 quarters · filed 2012-05-10 | -$401.00K 10-Q · filed 2012-05-10 | |
| 2010-12-31 | -$381.00K 10-Q · filed 2012-02-07 | -$337.00K 10-Q · filed 2012-02-07 | ||
| 2010-09-30 | $44.00K 10-Q · filed 2011-11-09 | |||
| 2010-06-30 | $175.00K 10-K · filed 2011-08-29 | |||
| 2009-06-30 | $2.16M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |